Risk groups of laryngeal cancer treated with chemoradiation according to nomogram scores - A pooled analysis of RTOG 0129 and 0522. Oral oncology Awan, M. J., Gittleman, H., Barnholtz-Sloan, J., Machtay, M., Nguyen-Tan, P. F., Rosenthal, D. I., Schultz, C., Huth, B. J., Thorstad, W. L., Frank, S. J., Kim, H., Foote, R. L., Lango, M. N., Shenouda, G., Suntharalingam, M., Harris, J., Zhang, Q., Le, Q., Yao, M., NRG Oncology Group 2021; 116: 105241


OBJECTIVES: To develop nomograms predicting overall survival (OS), freedom from locoregional recurrence (FFLR), and freedom from distant metastasis (FFDM) for patients receiving chemoradiation for laryngeal squamous cell carcinoma (LSCC).MATERIAL AND METHODS: Clinical and treatment data for patients with LSCC enrolled on NRG Oncology/RTOG 0129 and 0522 were extracted from the RTOG database. The dataset was partitioned into 70% training and 30% independent validation datasets. Significant predictors of OS, FFLR, and FFDM were obtained using univariate analysis on the training dataset. Nomograms were built using multivariate analysis with four a priori variables (age, gender, T-stage, and N-stage) and significant predictors from the univariate analyses. These nomograms were internally and externally validated using c-statistics (c) on the training and validation datasets, respectively.RESULTS: The OS nomogram included age, gender, T stage, N stage, and number of cisplatin cycles. The FFLR nomogram included age, gender, T-stage, N-stage, and time-equivalent biologically effective dose. The FFDM nomogram included age, gender, N-stage, and number of cisplatin cycles. Internal validation of the OS nomogram, FFLR nomogram, and FFDM nomogram yielded c=0.66, c=0.66 and c=0.73, respectively. External validation of these nomograms yielded c=0.59, c=0.70, and c=0.73, respectively. Using nomogram score cutoffs, three risk groups were separated for each outcome.CONCLUSIONS: We have developed and validated easy-to-use nomograms for LSCC outcomes using prospective cooperative group trial data.

View details for DOI 10.1016/j.oraloncology.2021.105241

View details for PubMedID 33640577